Brady, Helen,Moutouh-De Parseval, Laure,Chan, Kyle W. H.
申请号：
AU2011202457
公开号：
AU2011202457B2
申请日:
2011.05.26
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
#$%^&*AU2011202457B220121108.pdf#####ABSTRACT The present invention is directed to the use of immunomodulatory compounds, particularly members of the class of compounds known as IMiDs ", and more specifically the compounds 4(Amino)-2-(2,6-dioxo(3-pipridyl))-isoindoline- 1,3-dione and 3-(4-amino-I -oxo-1,3dihydroisoindol-2-yl)-piperidine-2,6-dione, to induce the expression of fetal hemoglobin genes, genes essential for erythropoiesis, and genes encoding alpha haemoglobin stabilizing protein, within a population of CD34* cells. These compounds are used to treat hemoglobinopathies such as sickle cell anemia or p-thalassemia, or anemias caused by disease, surgery, accident, or the introduction or ingestion of toxins, poisons or drugs.
